{"_id":"AOuMvKpb6xYzIbrmmmmm0xhyV07Wsq6QZnaV9VRy36Mp0Lf87phXsc","lastupdate":"2023-08-15T00:00:00.000Z","update_date":"2023-08-15T00:00:00.000Z","lastModified":"Mar 19, 2025","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"emris-pharma","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$ydRufQwZ0mAHJUV3i2SSfmkUcvOh7uqbBk2mYFOp5KF0OF2NpqHmOR.jpeg","name":"Emris Pharma","oneliner":"Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients","registrar":"516743176","website":"https://emris-pharma.com/","careerspage":"","founded_month":5,"founded_year":2023,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/93267280","instagram":""},"social":["https://www.linkedin.com/company/93267280"],"flattenedsociallinks":"https://www.linkedin.com/company/93267280","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":6,"patent":1,"raised":0,"stage":"Pre-Seed","public_stage":"Pre-Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy.\n\nCurrent treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment.\n\nIts solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies.\n\nSDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.","climatetech_description":null,"is_climatetech_relevant":null,"phone":null,"country":null,"address":{"israeli":[{"id":"y7wJzKM5X9Sj9bVBMyFl3ScR5nVnS60l0r3DxdXVQTZq45buf4boMv","city":"Nazareth","type":null,"address":"Wadi el-Haj St 13, Nazareth, Israel","placeid":null,"notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":null,"news":[{"id":"EgW04lBMSmrTO4FmKUA1JNYEowx1X9W36svKQBYiRqM7ND7nPkAYJV","date":"Jul 31, 2023","link":"https://www.calcalistech.com/ctechnews/article/r1iz3yhj2","source":"www.calcalistech.com","visible":1,"analysis":{"tags":["cancer treatment"],"company":"EMRIS Pharma","layoffs":null,"summary":"EMRIS Pharma has raised $422,000 to develop a novel small molecule therapy to prevent skin toxicities induced by EGFR inhibitors in cancer patients. The company aims to enhance the quality of life for cancer patients by proactively blocking the drug-receptor interaction that causes skin toxicity. The therapy targets the root cause of the toxicities and is expected to allow patients to maintain their daily lives without compromising their anti-cancer treatments. EMRIS Pharma has an entirely female executive team and plans to begin human trials within three years. The recent investment round of $422,000 was led by the Israel Innovation Authority and NGT Healthcare II. The companys innovative solution addresses a significant need in the market and has the potential to revolutionize cancer treatment.","partners":null,"customers":null,"investors":["Israel Innovation Authority","NGT Healthcare II"],"confidence":9,"key_topics":["cancer treatment","skin toxicities","EGFR inhibitors","topical therapy","clinical trials"],"date_of_event":"May 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":422000,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fqmxwaFCFCNqsxbzJCRtefGp1KaOCNfzfdKrB3Qlt9eboTKG3AZrEP","news_summary":"\"We can bring relief, improve quality of life, and ensure better compliance with treatment for cancer patients\" | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3SRwtr7R2heVNFUlK6pBC0ZYWChDx5SiSmXeyYVJ8jJ9Lb7IJLukdW","date":"Jun 8, 2023","link":"https://www.prnewswire.com/news-releases/emris-pharma-the-recent-spin-off-of-hadasit-and-yissum-launches-the-development-of-a-new-innovative-topical-drug-for-the-treatment-of-skin-toxicities-improving-treatment-and-quality-of-life-for-cancer-patients-301846387.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"skin toxicities, cancer treatment, research","company":"EMRIS Pharma","layoffs":null,"summary":"EMRIS Pharma, a spin-off of Hadasit and Yissum, is pioneering novel small molecule-based topical compounds to treat skin toxicities caused by EGFRi in cancer patients. The companys first product aims to improve the quality of life and treatment compliance for patients experiencing papulopustular skin rash. EMRIS Pharma has licensed the technology from Hadasit and Yissum, with NGT Healthcare2 VC as the founding investor. The lead compound developed by EMRIS Pharma has shown initial success in blocking EGFRi monoclonal antibodies. The companys innovative approach has the potential to significantly benefit cancer patients and increase treatment compliance. The event described in the article is the spin-off of EMRIS Pharma and the development of their novel cancer treatment product.","partners":"Hadasit, Yissum","customers":null,"investors":"NGT Healthcare2 VC","confidence":8,"key_topics":["Skin toxicities","EGFRi","Cancer treatment","Research","Collaboration"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oCzaFQS24DxN6Nsv843LVMmruHhazD5kaXwIih9dcmkmaLk1csOeBh","news_summary":"EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":2,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pharmaceuticals","cancer","skin","cancer-therapy","skin-care"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["EMR-001","SDT 011"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Pre-Seed","totalfunding":"Undisclosed","publicinvestors":2,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Lyora  Aharonov","email":"lyora@emris-pharma.com","phone":"","gender":"Female","userid":"3HNVfaku8VAwL2YxXiblK7vvdvFTIJvveyVkWERDLSd593i9Nxn2kT","bounced":false,"claimed":1,"founder":1,"urlname":"lyora-aharonov-1","visible":1,"memberid":"KbioSpfIjVjq6hN53qrzYtMjd8f4gYhv3xt1FWKo2ScvJJF0Y56kHS","position":"Co-founder & CEO","last_name":"Aharonov","claimtoken":"Zd4czW4U5E8REjvKP1kKBHvZSqxrxTRdifGDDF4BbkMVZQ1Lv7OJeN","first_name":"Lyora ","picturekey":"$IveVmV7sygzhrCvJM6BwiMkqLTAFfsaYBvgSU13HF8YaXtEcLoGTzd.jpeg","claimeddate":"2025-03-19","linkedinurl":"https://www.linkedin.com/in/lyora-aharonov/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2025-03-19 11:52:30.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$IveVmV7sygzhrCvJM6BwiMkqLTAFfsaYBvgSU13HF8YaXtEcLoGTzd.jpeg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sharon  Merims","email":"sharon@emris-pharma.com","phone":"","gender":"Female","userid":"vsIcIcbR8eFEjAFApJSUYveEYlBJFuixqHkpGYVxum3WmGXGJd0YRu","bounced":false,"claimed":null,"founder":0,"urlname":"sharon-merims-1","visible":1,"memberid":"qLgaBRA4vqLP2tAvEUWLPuCtjhvPox1JXlkIU97i2EhxoBAz8gk89v","position":"CSO","last_name":"Merims","claimtoken":"2XgOXHdQ91pONAX9fUpYjLldnfH0fvdpq4Nre2KgCJjy68RhUtxpdr","first_name":"Sharon ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dr-sharon-merims-5047485b/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2025-03-19 11:52:34.000000","initials":"SM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":null,"tag_line_edited":null,"sector":"Life Sciences & HealthTech","sectorverify":null,"biverify":{"id":"c9EsgAuuvwml0IzyIKWmOxLUUF5GjptiIXjHR1tp2gTB0O2GoGTfCd","fullname":"Yanina Wainscheinker"},"biverifydate":"2023-08-15T00:00:00.000Z","crunchbaseid":null,"lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Ortal Wein","creator_email":"ortalw@sncentral.org","createdate":"2023-03-29T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"zmPxljnhQ4aqlysVtCkqiI64jXz8ZT2Vf8jGcUKeZ9D4GeRfHu7Llr","date":"May 2023","amount":"Undisclosed","source":"Tamar- NGT Healthcare2","eventtype":"FundingRoundEvent","investment":[{"name":"NGT HealthCare II","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt-healthcare-ii","logokey":"$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","tagline":null,"urlname":"/investor_page/ngt-healthcare-ii","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIyLpeMIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"VBeL17NEfjdY9GCtGZ5CUWTZ6XkWqa9HmFHkjCGOjSNHp2FNu0nRHm","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Israel Innovation Authority","type":"Government","amount":null,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"BSyYlDESPttf4mNaPYXyutB192P9pjAPxibwF76l024RrCR6ml8NDH","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"5/2023","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Emris Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$ydRufQwZ0mAHJUV3i2SSfmkUcvOh7uqbBk2mYFOp5KF0OF2NpqHmOR.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$ydRufQwZ0mAHJUV3i2SSfmkUcvOh7uqbBk2mYFOp5KF0OF2NpqHmOR.jpeg","seoabout":"EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This in...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"zmPxljnhQ4aqlysVtCkqiI64jXz8ZT2Vf8jGcUKeZ9D4GeRfHu7Llr","date":"May 2023","amount":"Undisclosed","source":"Tamar- NGT Healthcare2","eventtype":"FundingRoundEvent","investment":[{"name":"NGT HealthCare II","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt-healthcare-ii","logokey":"$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","tagline":null,"urlname":"/investor_page/ngt-healthcare-ii","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIyLpeMIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"VBeL17NEfjdY9GCtGZ5CUWTZ6XkWqa9HmFHkjCGOjSNHp2FNu0nRHm","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Israel Innovation Authority","type":"Government","amount":null,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"BSyYlDESPttf4mNaPYXyutB192P9pjAPxibwF76l024RrCR6ml8NDH","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}